AU1395399A - Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis - Google Patents

Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis Download PDF

Info

Publication number
AU1395399A
AU1395399A AU13953/99A AU1395399A AU1395399A AU 1395399 A AU1395399 A AU 1395399A AU 13953/99 A AU13953/99 A AU 13953/99A AU 1395399 A AU1395399 A AU 1395399A AU 1395399 A AU1395399 A AU 1395399A
Authority
AU
Australia
Prior art keywords
protein
nucleic acid
group
seq
chag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13953/99A
Other languages
English (en)
Inventor
David G. Lowe
Richard A. Shimkets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Publication of AU1395399A publication Critical patent/AU1395399A/en
Priority to AU2003203787A priority Critical patent/AU2003203787B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
AU13953/99A 1997-11-10 1998-11-10 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis Abandoned AU1395399A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003203787A AU2003203787B2 (en) 1997-11-10 2003-04-17 Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6504897P 1997-11-10 1997-11-10
US60065048 1997-11-10
US09189618 1998-11-09
US09/189,618 US6610480B1 (en) 1997-11-10 1998-11-09 Treatment and diagnosis of cardiac hypertrophy
PCT/US1998/023953 WO1999024571A2 (en) 1997-11-10 1998-11-10 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003203787A Division AU2003203787B2 (en) 1997-11-10 2003-04-17 Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis

Publications (1)

Publication Number Publication Date
AU1395399A true AU1395399A (en) 1999-05-31

Family

ID=26745148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13953/99A Abandoned AU1395399A (en) 1997-11-10 1998-11-10 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis

Country Status (6)

Country Link
US (1) US6610480B1 (cg-RX-API-DMAC7.html)
EP (1) EP1030916A2 (cg-RX-API-DMAC7.html)
JP (2) JP2002508923A (cg-RX-API-DMAC7.html)
AU (1) AU1395399A (cg-RX-API-DMAC7.html)
CA (1) CA2309360A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999024571A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875567B1 (en) 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
EP1311704A2 (en) * 2000-05-30 2003-05-21 Medigene AG Novel target genes for diseases of the heart
DE10126371A1 (de) * 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
WO2002103355A1 (fr) * 2001-06-18 2002-12-27 Takeda Chemical Industries, Ltd. Agents prophylactiques/remedes pour maladies cardiaques
WO2003006687A2 (en) * 2001-07-10 2003-01-23 Medigene Ag Novel target genes for diseases of the heart
ITMI20012205A1 (it) * 2001-10-22 2003-04-22 Nanorganics Llc Metodo e mezzi per l'identificazione precoce di rischi di scompenso cardiaco
US7482132B2 (en) 2001-12-13 2009-01-27 Sanofi-Aventis Deutschland Gmbh Method for determining the activity of ornithine decarboxylase and for identifying effectors of ornithine decarboxylase activity
DE10161412A1 (de) * 2001-12-13 2003-07-03 Aventis Pharma Gmbh Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität
WO2003059948A1 (en) * 2002-01-15 2003-07-24 Medigene Ag Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes
ES2770067T3 (es) 2004-05-11 2020-06-30 Ncardia Ag Descubrimiento de fármacos basado en células diferenciadas in vitro
US20070179815A1 (en) * 2006-01-20 2007-08-02 Heartscreen America, Inc. Medical screening system and method
EP2046997A2 (en) * 2006-07-25 2009-04-15 Deutsches Krebsforschungszentrum A common gene expression signature in dilated cardiomyopathy
EP2347265A1 (en) * 2008-10-17 2011-07-27 Roche Diagnostics GmbH Use of biglycan in the assessment of heart failure
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0755446T3 (da) * 1994-04-25 2007-01-29 Genentech Inc Cardiotrophin og anvendelser deraf
US5972693A (en) 1995-10-24 1999-10-26 Curagen Corporation Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing

Also Published As

Publication number Publication date
WO1999024571A3 (en) 1999-08-26
WO1999024571A2 (en) 1999-05-20
US6610480B1 (en) 2003-08-26
EP1030916A2 (en) 2000-08-30
JP2007135219A (ja) 2007-05-31
JP2002508923A (ja) 2002-03-26
CA2309360A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
US6486299B1 (en) Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6610480B1 (en) Treatment and diagnosis of cardiac hypertrophy
AU5575999A (en) Leptin-related peptides
CA2301862A1 (en) Atrial natriuretic factor mutants and ischemic stroke
EP1124572B1 (en) Genes and proteins predictive and therapeutic for renal disease and associated disorders
US20040167066A1 (en) Cleavage and polyadenylation complex of precursor mrna
US6875567B1 (en) Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US20020164735A1 (en) Methods and compositions relating to a cardiac-specific nuclear regulatory factor
CA2496891A1 (en) Novel actin-related cytoskeletal protein lacs
Germain-Lee et al. NVL: a new member of the AAA family of ATPases localized to the nucleus
AU2003203787B2 (en) Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis
WO2008110356A2 (en) Protein pi 16 secreted from the heart and uses thereof
WO1999033987A1 (en) Cloning of a high growth gene
AU2006225276A1 (en) Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis
AU2004223739A1 (en) Cyclic AMP response element activator proteins and uses related thereto
US20040241807A1 (en) Interleukin-1 related gene and protein
EP1406665A2 (en) Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis
EP1345962A2 (en) Methods and compositions relating to cardiac-specific nuclear regulatory factors
JP3629759B2 (ja) プロテアソームアクチベーター
US20060264610A1 (en) Protein complexes of the tip60 transcriptional activator protein
JPWO2002064770A1 (ja) 新規スカベンジャー受容体クラスa蛋白質
WO1997043415A1 (en) Cyclin d binding factor, and uses thereof
Stuermer Analysis of the reticulon gene family demonstrates the absence of the neurite growth inhibitor Nogo-A in fish
AU2002249874A1 (en) Methods and compositions relating to a cardiac-specific nuclear regulatory factors
WO2002046420A2 (en) Nebulin-related protein

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted